For investors, will 2005 be the best of years, the worst of years, or something in between? At first glance, the outlook would appear to be for a somewhat ho hum, business-as-usual 12 months. With inflation by most measures at 2 to 3 percent, and the P/Es… Read More

Old news is good news   THE OUTLOOK: The world’s population is aging. HOW TO PROFIT: Health care and insurance companies will be among the biggest beneficiaries.   At its most basic, smart investing comes down to identifying surefire long-term trends… Read More

They cater to our ailing joints, our failing eyes, and our demand for drugs   Let’s get right down to the remaining three demographically favored health care stocks from the table on p.2.   First up is one we’re adding to Growth Portfolio this issue:… Read More

Take a big profit in SL Green but continue to hold onto Regency   REITs have sure been hot. The Morgan Stanley REIT index soared 29 percent in the first 11 months of 2004, following a 36 percent rise in 2003—a winning streak that means a… Read More

Berwyn and CGM Focus offer considerable diversification appeal   Two more FundFolio veterans—small value fund Aegis Value and small blend fund Royce Low Priced Stock—have performed so well, thereby attracting so much money, that they’re now closed to new investors. If you… Read More

Why we’re dumping Clear Channel and OmniVision   This issue, as we do periodically, we’re engaging in some housecleaning. We’ve reviewed all our recommendations and in particular we’ve looked to see if they still are important holdings of the funds that originally brought them to our… Read More

Sepracor’s new insomnia drug should let you rest easy   Have you been having trouble sleeping lately? Have you tried, unsuccessfully, a new mattress? Warm milk? Counting sheep? If none of this helped, you—along with millions of other Americans—may soon be begging your doctor to prescribe… Read More

Coal, that dirty fuel of the past, is also a fuel of the future   In the 1960s, oil surpassed coal as the world’s primary energy source. But coal, for all the environmental and health-related strikes against it, has never gone away entirely—far from it. It… Read More

Michael Milken: An Instructive Life   Michael Milken has been described in many ways – as financial innovator, villain, philanthropist, and devoted family man. Perhaps the most apt term, though, is survivor.   In the 1970s and ’80s, at Drexel Burnham Lambert, Milken made a… Read More

The fiscal gap could jump to $85 trillion, way beyond our borrowing power   Editor’s note: Dan Shaviro, drawing attention to our record budget and trade deficits, shows the urgency of diversifying into investments that will benefit from a falling dollar. Dan argues that almost anything could… Read More